View More Recent Stories
-
Krystal Biotech (KRYS) Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
-
BofA Securities Reiterates Buy Rating on Krystal Biotech (KRYS)
-
Krystal Biotech (KRYS) Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
-
Krystal Biotech (KRYS) PT Raised to $206 at Citi
-
Krystal Biotech, Inc. (KRYS) Misses Q3 EPS by 8c
-
Stifel Reiterates Buy Rating on Krystal Biotech (KRYS)
-
TD Cowen Reiterates Buy Rating on Krystal Biotech (KRYS)
-
Krystal Biotech (KRYS) PT Raised to $221 at H.C. Wainwright
-
Stifel Reiterates Buy Rating on Krystal Biotech (KRYS)
-
Krystal Biotech's (KRYS) Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301
-
Krystal Biotech, Inc. (KRYS) Misses Q2 EPS by 25c Provides Outlook

